IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer
Liu, Yin; Xu, Ye; Ouyang, Tao; Li, Jinfeng; Wang, Tianfeng; Fan, Zhaoqing; Fan, Tie; Lin, Benyao; Xie, Yuntao
刊名BMC CANCER
2015-03-28
DOI10.1186/s12885-015-1203-3
15
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]PATHOLOGICAL COMPLETE RESPONSE ; CHECKPOINT KINASE CHK2 ; POLY(ADP-RIBOSE) POLYMERASE ; TUMOR CHARACTERISTICS ; GERMLINE MUTATION ; YOUNG-WOMEN ; DNA-DAMAGE ; CHEK2-ASTERISK-1100DELC ; POPULATION ; CELLS
英文摘要

Background: Our previous study suggested that the recurrent CHEK2 H371Y mutation is a novel pathogenic mutation that confers an increased risk of breast cancer. The purpose of this study was to investigate whether breast cancer patients with CHEK2 H371Y mutation were more likely to respond to neoadjuvant chemotherapy. Methods: We screened a cohort of 2334 Chinese women with operable primary breast cancer who received a neoadjuvant chemotherapy regimen for CHEK2 H371Y germline mutations. Pathologic complete response ( pCR) was defined as the absence of tumor cells in the breast after the completion of neoadjuvant chemotherapy. Results: Thirty- nine patients ( 1.7%) with CHEK2 H371Y germline mutation were identified in this cohort of 2334 patients. CHEK2 H371Y mutation carriers had a significantly higher pCR rate than non- carriers ( 33.3% versus 19.5%, P = 0.031) in the entire study population, and CHEK2 H371Y mutation- positive status remained an independent favorable predictor of pCR in a multivariate analysis ( odds ratio [ OR] = 3.01; 95% confidence interval [ CI]: 1.34- 6.78, P = 0.008). CHEK2 H371Y carriers had a slightly worse distant recurrence- free survival than non- carriers ( adjusted hazard ratio [ HR] = 1.24, 95% CI: 0.59- 2.63). Conclusions: CHEK2 H371Y mutation carriers are more likely to respond to neoadjuvant chemotherapy than are non- carriers.

语种英语
WOS记录号WOS:000351813400001
引用统计
被引频次:2[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52790
专题北京大学临床肿瘤学院
北京大学临床肿瘤学院_乳腺癌预防治疗中心
北京大学临床肿瘤学院_乳腺中心实验室
作者单位Peking Univ, Canc Hosp, Beijing Canc Hosp & Inst,Minist Educ, Breast Ctr,Key Lab Carcinogenesis & Translat Res, Beijing 100142, Peoples R China
推荐引用方式
GB/T 7714
Liu, Yin,Xu, Ye,Ouyang, Tao,et al. Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer[J]. BMC CANCER,2015,15.
APA Liu, Yin.,Xu, Ye.,Ouyang, Tao.,Li, Jinfeng.,Wang, Tianfeng.,...&Xie, Yuntao.(2015).Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer.BMC CANCER,15.
MLA Liu, Yin,et al."Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer".BMC CANCER 15(2015).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Liu, Yin]的文章
[Xu, Ye]的文章
[Ouyang, Tao]的文章
百度学术
百度学术中相似的文章
[Liu, Yin]的文章
[Xu, Ye]的文章
[Ouyang, Tao]的文章
必应学术
必应学术中相似的文章
[Liu, Yin]的文章
[Xu, Ye]的文章
[Ouyang, Tao]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。